Isosceles Pharmaceuticals
Early Stage
Helping Solve America's Opioid Crisis
Overview
Raised: $5,000,000
Total Commitments ($USD)
Platform
Equifund
Start Date
10/03/2022
Close Date
04/30/2023
Min. Goal
$20,000
Max. Goal
$5,000,000
Min. Investment
$500
Security Type
Equity - Common
Series
Seed
SEC Filing Type
RegCF
Price Per Share
$2.05
Pre-Money Valuation
$30,800,000
Rolling Commitments ($USD)
Status
Funded
Reporting Date
05/01/2023
Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise
$24,038
Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded
2019
Industry
Healthcare & Pharmaceuticals
Tech Sector
Medtech
Distribution Model
B2B
Margin
Medium
Capital Intensity
High
Isosceles Pharmaceuticals, with a valuation of $30.8 million, is raising funds on Equifund CFP. It is a pharmaceutical company currently developing intravenous formulations of synthetic Cannabidiol as non-addictive alternatives to opium-based painkillers. The CBD formulations will be used for acute post-operative pain and will address the surgical population in the US, Europe, and the UK. Isosceles Pharmaceuticals is currently in the pre-clinical trials stage. Brett Lanier founded Isosceles Pharmaceuticals in April 2019. The current crowdfunding campaign has a minimum target of $20,000 and a maximum target of $5 million. The campaign proceeds will be used to fund pre-clinical animal trials and IND filings for a new intravenous drug delivery system.
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$0 |
$0 |
|
COGS |
$0 |
$0 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$879,786 |
$891,911 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$212,834 |
$198,240 |
|
Accounts Receivable |
$0 |
$0 |
|
Total Assets |
$212,834 |
$198,240 |
|
Short-Term Debt |
$0 |
$0 |
|
Long-Term Debt |
$120,000 |
$0 |
|
Total Liabilities |
$120,000 |
$0 |
Financials as of: 10/03/2022
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Already a member? Log in here.
Ratings 
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.